Jubilant Ingrevia Q1 FY27 Results: Revenue ₹13,003 Crore, Net Profit ₹105.82 Crore
Jubilant Ingrevia reported Q1 FY27 consolidated revenue from operations at ₹13,003 crore and net profit at ₹105.82 crore. Standalone net profit was ₹126.22 crore. The company's Board of Directors approved these unaudited financial results on July 22, 2026.
The results provide key financial figures for the quarter, which are important for investors and stakeholders to assess the company's performance. This information directly influences investment decisions and market perception.
The announcement reports financial results which are factual in nature. While the numbers are presented, there is no explicit commentary or forward-looking guidance that would strongly sway the sentiment as positive or negative.
Jubilant Ingrevia Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on July 22, 2026. The company reported a total consolidated income of ₹131,049 lakh (₹1310.49 crore) for the quarter. Expenses amounted to ₹116,960 lakh (₹1169.60 crore), leading to a profit before tax of ₹14,086 lakh (₹140.86 crore). After accounting for tax expenses of ₹4,296 lakh (₹42.96 crore), the net profit for the period stood at ₹10,582 lakh (₹105.82 crore). The total comprehensive income for the period was ₹11,058 lakh (₹110.58 crore).
On a standalone basis, the company reported a total income of ₹126,322 lakh (₹1263.22 crore) and total expenses of ₹109,361 lakh (₹1093.61 crore). This resulted in a profit before tax of ₹16,961 lakh (₹169.61 crore). The tax expense was ₹3,959 lakh (₹39.59 crore), leading to a net profit of ₹12,622 lakh (₹126.22 crore). The total comprehensive income on a standalone basis was ₹12,626 lakh (₹126.26 crore).
The company also provided segment-wise details. For consolidated operations, Speciality Chemicals contributed ₹83,700 lakh in segment revenue, Nutrition & Health Solutions ₹24,382 lakh, and Chemical Intermediates ₹52,517 lakh. The segment results (profit before tax and interest) were ₹10,914 lakh for Speciality Chemicals, ₹2,826 lakh for Nutrition & Health Solutions, and ₹4,397 lakh for Chemical Intermediates. The limited review report on the financial results was issued by Walker Chandiok & Co LLP.
What to do with a filing like this
Jubilant Ingrevia Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Ingrevia Limited. Read the original for the full detail.